secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004049
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom announces positive Ph3 NERD-301 topline results for vonoprazan; both doses met primary endpoint
--------------------------------------------------------------------------------

- Vonoprazan 10 mg and 20 mg both achieved significantly greater 24-hour heartburn-free days vs placebo (46.4% and 46.0% vs 27.5%; p<0.0001).
- Median percentage of heartburn-free days: 48.3% (10 mg), 46.7% (20 mg), 17.0% (placebo).
- Safety profile comparable to placebo; most common AE was nausea (2.3% 10 mg, 3.1% 20 mg, 0.4% placebo).
- Blinded 20-week long-term extension ongoing; full results expected later in 2023.
- Discussions with FDA ongoing regarding separate Phase 3 trial for on-demand dosing in NERD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312523004049/0001193125-23-004049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312523004049/d432177d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer